Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24079246 | 0.95 | NAMPT (0.41) | NAMPTCMKLR1LMNAGAAHSD17B10 | |
| SCHEMBL24263762 | 0.94 | LMNA (0.39) | NAMPTCMKLR1LMNAGAAMTNR1A | |
| SCHEMBL25481294 | 0.90 | NAMPT (0.41) | NAMPTCMKLR1LMNAMTNR1AMTNR1B | |
| SCHEMBL24928124 | 0.89 | NAMPT (0.45) | NAMPTCMKLR1LMNAGAAMTNR1A | |
| SCHEMBL18737173 | 0.88 | LMNA (0.39) | NAMPTCMKLR1LMNAHSD17B10MAPT | |
| SCHEMBL24079245 | 0.85 | LMNA (0.44) | CMKLR1LMNAHSD17B10MAPTMEN1 | |
| SCHEMBL22898099 | 0.85 | NAMPT (0.41) | NAMPTLMNAGAAMTNR1AMTNR1B | |
| SCHEMBL24263804 | 0.85 | LMNA (0.37) | NAMPTCMKLR1LMNAHSD17B10MAPT | |
| SCHEMBL22965566 | 0.84 | CMKLR1 (0.38) | NAMPTCMKLR1LMNAGAAMTNR1A | |
| SCHEMBL23962075 | 0.83 | LMNA (0.36) | CMKLR1LMNAMTNR1AMTNR1BHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11191841-B2 | Supramolecular modification of proteins | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11191841-B2 | Supramolecular modification of proteins | IAPP, PTMS, GLP1R | NAMPT 3552/4885CMKLR1 2375/4885LMNA 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.